Jamie Dimon Warns Anthropic's Mythos AI Poses National Security Risks 
Airbus Signs Cloud Deal With Scaleway to Power Secure AI and Defense Applications 
DBS Targets S$1 Trillion Wealth AUM by 2030 Amid Asia Wealth Boom 
Eli Lilly Eyes AtaiBeckley Acquisition to Expand Psychedelic Mental Health Pipeline 
ASML Raises 2026 Outlook as AI Chip Demand Lifts Q2 Earnings 
Hyundai Takes Full Control of Boston Dynamics to Accelerate Humanoid Robot and AI Strategy 
Sodexo Unveils Shift & Grow 2030 Strategy, Targets Over 5% Revenue Growth by Fiscal 2030 
Volkswagen Launches €28,000 ID. Cross EV as Europe’s Electric Vehicle Demand Accelerates 
Rio Tinto Reports Strong Q2 Iron Ore Sales, Maintains 2026 Production Outlook 
SpaceX Stock Falls Below IPO Price as Investors Weigh Losses and Lockup Expiry 
Paramount-Warner Bros. Discovery Merger Faces Lawsuit From 12 States 
SK Hynix Stock Soars as AI Memory Demand Outlook Fuels Chip Rally 
Arm Stock Falls After HSBC Downgrade, Citing Limited Near-Term AI Upside 
Richemont Q1 Sales Beat Forecast as Cartier Demand Drives Strong Growth 
Uber to Acquire Delivery Hero in $14.8 Billion Deal to Expand Global Food Delivery Business 
Apple Intelligence Cleared for China as Alibaba and Baidu AI Power iPhone Features 
Taiwan Mangoes Head to Europe as Premium Fruit Exports Expand 
CAMBRIDGE, Mass., Feb. 01, 2016 -- Momenta Pharmaceuticals, Inc. (NASDAQ:MNTA), a biotechnology company specializing in the characterization and engineering of complex drugs, today announced that it will webcast its presentation at two upcoming investor conferences.
Leerink Partners 5th Annual Global Healthcare Conference
Wednesday, February 10, 2016 at 8:50 a.m. ET in New York, NY
RBC Capital Markets’ 2016 Global Healthcare Conference
Tuesday, February 23, 2016 at 4:05 p.m. ET in New York, NY
The audio webcast of the presentation will be available live on the “Investors” section of the company’s website located at www.momentapharma.com. A replay of the presentation will be posted on the Momenta website approximately one hour after the event and will be available for two weeks following the presentation.
About Momenta
Momenta Pharmaceuticals is a biotechnology company specializing in the detailed structural analysis of complex drugs and is headquartered in Cambridge, MA. Momenta is applying its technology to the development of generic versions of complex drugs, biosimilar and potentially interchangeable biologics, and to the discovery and development of novel therapeutics for oncology and autoimmune indications.
To receive additional information about Momenta, please visit the website at www.momentapharma.com, which does not form a part of this press release.
Our logo, trademarks, and service marks are the property of Momenta Pharmaceuticals, Inc. All other trade names, trademarks, or service marks are property of their respective owners.
Sarah Carmody Momenta Pharmaceuticals 1-617-395-5189 [email protected]
